Cholesterol drug shows promise against advanced breast cancer in new trial
NCT ID NCT02958852
First seen Sep 30, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tested whether adding the cholesterol-lowering drug atorvastatin to standard hormone therapy (letrozole, fulvestrant, or aromatase inhibitors) could better control advanced breast cancer. 126 women with ER-positive, HER2-negative advanced breast cancer took part. The main goal was to see if the combination improved the rate of tumor shrinkage or stable disease over 24 weeks, and to understand how resistance to hormone therapy develops.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lund University Hospital, Department of Oncology
Lund, 221 85, Sweden
Conditions
Explore the condition pages connected to this study.